These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 6431431

  • 21. [Clinical effects of FEIBA on hemophilia patients with inhibitors to factor VIII or IX].
    Iizuka A, Kuwashima M, Nagao T.
    Nihon Ketsueki Gakkai Zasshi; 1982 Sep; 45(5):987-92. PubMed ID: 6818811
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. [In-vivo control of blood coagulation fractions].
    Richter K, Rex JO, Stinner G, Fünfhausen G.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1970 Sep; 93(3):344-8. PubMed ID: 4195280
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. [Immune coagulation disorders (excluding antiphospholipid syndrome].
    Arai M.
    Rinsho Byori; 2001 Oct; 49(10):1000-4. PubMed ID: 11769464
    [Abstract] [Full Text] [Related]

  • 28. Measurement of human factor IXa activity in an isolated factor X activation system.
    Griffith MJ, Reisner HM, Lundblad RL, Roberts HR.
    Thromb Res; 1982 Aug 01; 27(3):289-301. PubMed ID: 6814005
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Failure of factor VIII inhibitor bypassing activity (Feiba) to secure haemostasis in haemophilic patients with antibodies.
    Parry DH, Bloom AL.
    J Clin Pathol; 1978 Nov 01; 31(11):1102-5. PubMed ID: 739057
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Abnormal T-lymphocyte subsets in hemophilia: relation to HLA proteins in plasma products.
    Lee CA, Kernoff PB, Karayiannis P, Waters J, Thomas HC.
    N Engl J Med; 1984 Apr 19; 310(16):1058. PubMed ID: 6424010
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Changes of antigenecity of blood clotting factors during the process of blood coagulation (author's transl)].
    Fujimaki M, Iematsu S, Kato M, Kogiso H, Matsubara Y.
    Rinsho Byori; 1978 Apr 19; 26(4):298-304. PubMed ID: 671776
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Hemophilia and von Willebrand's disease: genetic considerations.
    Green D.
    Ann Clin Lab Sci; 1980 Apr 19; 10(2):123-7. PubMed ID: 6770741
    [Abstract] [Full Text] [Related]

  • 38. HLA-DR and Factor VIII antibodies in hemophilia A.
    Mayr WR, Lechner K, Niessner H, Pabinger-Fasching I.
    Thromb Haemost; 1984 Apr 30; 51(2):293. PubMed ID: 6429887
    [No Abstract] [Full Text] [Related]

  • 39. Inhibitors in congenital coagulation disorders.
    Key NS.
    Br J Haematol; 2004 Nov 30; 127(4):379-91. PubMed ID: 15521914
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.